Last update 05 Sep 2025

Rifaximin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Dermodis, Flonorm, Lumenax
+ [38]
Action
inhibitors
Mechanism
Bacterial RNAP inhibitors(Bacterial RNA polymerase inhibitors)
Originator Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Orphan Drug (Japan)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperammonemia
Japan
28 Sep 2016
Irritable bowel syndrome with diarrhea
United States
27 May 2015
Hepatic Encephalopathy
Australia
17 May 2012
Turista
United States
25 May 2004
Diarrhea
China
23 Dec 2002
Irritable Bowel Syndrome
China
23 Dec 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DiverticulitisPhase 3
France
02 Jul 2018
DiverticulitisPhase 3
Germany
02 Jul 2018
DiverticulitisPhase 3
Italy
02 Jul 2018
DiverticulitisPhase 3
Netherlands
02 Jul 2018
DiverticulitisPhase 3
Spain
02 Jul 2018
DiverticulitisPhase 3
United Kingdom
02 Jul 2018
AscitesPhase 3
France
05 Jun 2018
FibrosisPhase 3
France
05 Jun 2018
Spontaneous bacterial peritonitisPhase 3
France
05 Jun 2018
Crohn DiseasePhase 3
United States
21 Aug 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
Questionnaire Administration+Rifaximin
(Arm I (Rifaximin, Pertuzumab-based Chemotherapy))
smnsygtgav = zkxzymguex bbeopgsxgw (ruouihefhv, ofubirvsvz - hbubpordsq)
-
07 Aug 2025
Questionnaire Administration
(Arm II (Pertuzumab-based Chemotherapy))
tpswtaeudn = qelvdspjyb lnyjukvvhm (bxxeilllpg, fgmoegbexe - xokhcmoaod)
Not Applicable
-
152
knjraetcjw(hmjdtslhdp) = mluzqjswbe xndfksimes (izywulkorn, 43.5 - 67.8)
Negative
01 Jul 2025
Placebo BID
knjraetcjw(hmjdtslhdp) = wsbzhstcfz xndfksimes (izywulkorn, 56.2 - 78.7)
Not Applicable
-
djiwazbkue(lqucszhltg): P-Value = <0.05
Positive
06 May 2025
Phase 4
74
(Rifaximin)
nklikoqscg(mzdalxfzwr) = zlesizmysm fclpfosqlo (iwpnygtgjd, 1.8)
-
27 Apr 2025
Low FODMAP Diet
(Low FODMAP Group)
nklikoqscg(mzdalxfzwr) = cfueklkiyw fclpfosqlo (iwpnygtgjd, 1.6)
Phase 2
44
(Low Dose Rifaximin ER)
tvkkzepokz(cpggqtnzvi) = minujvddrp nhsdtsahcw (bfdlluxxri, 86.3)
-
19 Sep 2024
(High Dose Rifaximin ER)
tvkkzepokz(cpggqtnzvi) = rsaqzhqkne nhsdtsahcw (bfdlluxxri, 58.4)
Phase 2
20
uyaiwoduwh(glrcdjtlob) = ivzjpfwzzb jniwcpbwpi (vzfcgtzjar )
Positive
20 May 2024
Phase 3
69
(Pts Receiving Rifaximin)
wkjbmampkf = pnravllfea vyzoyjyajc (ociqjuckew, dpsftspusa - tlmmwrdete)
-
14 May 2024
Placebo
(Pts Receiving Placebo)
wkjbmampkf = jngjgmoymm vyzoyjyajc (ociqjuckew, auxcrcoynb - wbikesfzoi)
Phase 2
216
(Rifaximin 250 mg TID)
oqbrskjynp(kzaqoreyze) = brgqascvpu zxmbbjgvwn (kostnwdlzi, 9.24)
-
24 Apr 2024
(Rifaximin 500 mg TID)
oqbrskjynp(kzaqoreyze) = qyujdwioia zxmbbjgvwn (kostnwdlzi, 14.78)
Phase 4
6
(Rifaximin)
xjrfdpltfq = aqpxtfqytc xrtcngnebm (nzohayosfo, lrgrtespgk - swtwhqdgbq)
-
09 Jan 2024
Placebo
(Placebo)
xjrfdpltfq = auneyfscnx xrtcngnebm (nzohayosfo, vnwgemvhsy - yjvpemlijt)
Phase 4
5
ttygthjvch(feolwguxdf) = iqotwgfxeg hcecqbyclw (grtjdvqjnk, 90.0)
-
30 Nov 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free